Revlimid Hits Target in Newly Diagnosed Myeloma Patients
By Catherine Shaffer
Staff Writer
Staff Writer
Celgene International Sarl's successful multiple myeloma drug, Revlimid (lenolidomide), met an important benchmark in newly diagnosed patients in a Phase III study.
